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Abstract  
BACKGROUND: There has been a great interest in the interaction between obstructive sleep 
apnea (OSA) and metabolic dysfunction, but there is no consistent data suggesting that OSA is a 
risk factor for dyslipidemia.  
AIM: The aim of this cross-sectional study was to evaluate the prevalence of lipid abnormalities in 
patients suspected of OSA, referred to our sleep laboratory for polysomnography.  
MATERIAL AND METHODS: Two hundred patients referred to our hospital with suspected OSA, 
and all of them underwent for standard polysomnography. All patients with respiratory disturbance 
index (RDI) above 15 were diagnosed with OSA. In the morning after 12 hours fasting, the blood 
sample was collected from all patients. Blood levels of triglycerides, total cholesterol, high-density 
lipoprotein cholesterol (HDL) and low-density lipoprotein cholesterol (LDL), were determined in all 
study patients. In the study, both OSA positive and OSA negative patients were divided according 
to the body mass index (BMI) in two groups. The first group with BMI ≤ 30 kg/m^2 and the second 
group with BMI > 30 kg/m^2. 
RESULTS: OSA positive patients with BMI ≤ 30 kg/m^2 had statistically significant higher levels of 
triglycerides and total cholesterol, and statistically significant lower level of HDL compared to OSA 
negative patients with BMI ≤ 30. There were no statistically significant differences in age and LDL 
levels between these groups. OSA positive patients with BMI > 30 kg/m^2 had higher levels of 
triglycerides, total cholesterol and LDL and lower levels of HDL versus OSA negative patients with 
BMI > 30 kg/m^2, but without statistically significant differences.  
CONCLUSION: OSA and obesity are potent risk factors for dyslipidemias. OSA could play a 
significant role in worsening of lipid metabolism in non-obese patients. But in obese patients, the 
extra weight makes the metabolic changes of lipid metabolism, and the role of OSA is not that very 
important like in non-obese patients.
 
 
 
 
Introduction 
 
Obstructive sleep apnea (OSA) is an 
increasingly prevalent condition that is characterised 
by repetitive upper airway obstructions resulting in 
intermittent hypoxia and sleep fragmentation caused 
by arousals [1]. Among adults, 30–70 years of age, 
approximately 13% of men and 6% of women, have 
moderate to severe forms of OSA [2]. OSA is often 
closely associated with other conditions which are 
recognised causes of morbidity and mortality such as 
obesity, metabolic syndrome, atherosclerosis, 
systemic inflammation, insulin resistance and type 2 
diabetes mellitus [3, 4]. Recently, there has been a 
great interest in the interaction between OSA and 
metabolic dysfunction. There is no consistent data 
suggesting that OSA is a risk factor for dyslipidemia. 
Indeed, conflicting results have been observed in 
cross-sectional and interventional studies [5]. Taking 
into account components of the metabolic syndrome, 
some reports found increased levels of triglycerides 
[6-9] and reduced levels of high-density lipoproteins 
(HDL) in patients with OSA [8-10], while others 
studies did not find the correlation between OSA and 
dyslipidemia [11,12]. Of note, the majority of the 
studies were not specifically designed to evaluate the 
lipid profile. Therefore, more evidence is still needed. 
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Increased understanding of the independent 
associations between OSA, metabolic syndrome and 
insulin resistance is important to develop appropriate 
therapeutic strategies to reduce the high 
cardiometabolic risks in patients with OSA.
 
 The aim of this cross-sectional study was to 
evaluate the prevalence of lipid abnormalities in 
patients suspected for OSA referred to our sleep 
laboratory for polysomnography. 
 
 
 
Material and Methods  
 
The study included 200 patients. It was 
conducted at University Clinic of Pulmonology and 
Allergy in Skopje. Inclusion criteria for patients were 
age from 35 to 60 years and persistence of minimum 
2 of 3 clinical symptoms of OSA. The symptoms were 
snoring, witnessed apnea and daytime sleepiness. 
Exclusion criteria were previous history and treatment 
of diabetes and lipid abnormalities.  
The study was approved by Ethical 
Committee of the Faculty of Medicine with No. 03-
941/2, and before the study procedures, informed 
consent was obtained from all patients. Body mass 
index (BMI) was calculated, and patients were divided 
into two groups according to the BMI. All patients 
underwent polysomnography (Respironix, model Alice 
5). All results from polysomnography were scored 
manually according to standard criteria [13]. Apnea, 
hypopnea and arousals were also identified according 
to the standard criteria and summarised in the form of 
a respiratory disturbance index (RDI). All patients with 
RDI above 15 were diagnosed with OSA. 
 
In the morning after 12 hours fasting, a blood 
sample was collected from all patients. Blood levels of 
triglycerides (TG), total cholesterol (TC), high-density 
lipoprotein cholesterol (HDL) and low-density 
lipoprotein cholesterol (LDL), were assessed. 
Biochemical measurements were conducted using an 
Architect Abbott C8000 auto analyser. 
 
Statistical analyses were performed using 
Statistical software (Stat Soft). Data were expressed 
as mean (X) and standard deviation (SD). 
Comparisons between variables were made using the 
unpaired t test for parametric data. The multiple linear 
regressions were used to determine the association 
between OSA and metabolic parameters. Statistical 
significance was considered at p less than 0.05.  
 
 
Results  
From all study patients, 51 were female with 
an average age of 49 ± 9 years, and 149 were men 
average age of 47 ± 9 years. There was no significant 
difference in age, BMI and RDI between male and 
female. There was the significant difference in the 
occurrence of OSA in men versus women, 109 
(73.2%) of males and 31 (62.8%) of females were 
OSA positive (p < 0.03).  
According to BMI, patients in the study were 
divided into two groups. There were 120 non-obese 
patients with BMI ≤ 30 kg/m^2, and 80 obese patients 
with BMI > 30 kg/m^2. In a non obese group with BMI 
≤ 30, 62 patients were OSA negative and 58 patients 
were OSA positive. In an obese group with BMI > 30, 
14 patients were OSA negative, and 66 patients were 
OSA positive (Figure 1). 
 
Figure 1: Frequency of OSA in study patients divided according to 
BMI. RDI = Respiratory disturbance index; BMI = Body mass index 
 
OSA patients had statistically significant 
higher BMI, triglycerides, total cholesterol and lower 
HDL when compared to OSA negative patients (Table 
1). There was no statistical difference in age and LDL 
levels between these two groups of patients. 
Table 1: Comparison between OSA positive and OSA negative 
patients 
 
OSA negative OSA positive 
 
 
RDI < 15                            
(76 patients) 
RDI > 15 
(124 patients) 
 
 
X SD X SD P 
RDI 5.04 3.81 43.78 18.71 0.000 
Age (years) 47.29 9.73 48.22 8.49 NS 
BMI (kg/m^2) 27.58 3.14 31.11 4.35 0.000 
TG (mmol/l) 1.60 0.36 1.76 0.26 0.000 
TC (mmol/l) 4.94 0.50 5.22 0.34 0.000 
HDL (mmol/l) 1.45 0.23 1.34 0.23 0.001 
LDL (mmol/l) 2.85 0.53 2.94 0.49 NS 
OSA = Obstructive sleep apnea; RDI = Respiratory disturbance index; BMI = Body mass 
index; TG = Triglycerides; TC = Total cholesterol; HDL= High-density lipoprotein 
cholesterol; LDL = Low-density lipoprotein cholesterol. 
 
In the study, both OSA positive and OSA 
negative patients were divided according to BMI in 
two groups, first group with BMI ≤ 30 and the second 
group with BMI > 30. OSA positive patients with BMI ≤ 
30 had statistically significant higher levels of 
triglycerides and total cholesterol, and statistically 
significant lower level of HDL compared to OSA 
negative patients with BMI ≤ 30. There were no 
statistically significant differences in age and LDL 
levels between these groups (Table 2). 
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Table 2: Comparison between OSA positive and OSA negative 
patients with BMI ≤ 30 
BMI ≤ 30 
 RDI < 15 (62 patients) RDI > 15 (58 patients)  
 X SD X SD p 
RDI 4.65 3.41 38.68 16.92 0.000 
Age (years) 47.08 9.56 47.62 8.38 NS 
BMI (kg/m^2) 26.55 2.40 27.38 1.80 0.035 
TG (mmol/l) 1.53 0.28 1.66 0.18 0.003 
TC (mmol/l) 4.90 0.49 5.10 0.28 0.010 
HDL (mmol/l) 1.55 0.22 1.35 0.19 0.000 
LDL (mmol/l) 2.84 0.52 2.79 0.36 NS 
RDI = Respiratory disturbance index; BMI = Body mass index; TG = Triglycerides; TC = 
Total cholesterol; HDL= High-density lipoprotein cholesterol; LDL = Low-density lipoprotein 
cholesterol. 
 
OSA positive patients with BMI>30 had higher 
triglycerides, total cholesterol and LDL and lower HDL 
versus OSA negative patients with BMI>30, but 
without statistically significant differences (Table 3.)
 
Table 3: Comparison between OSA positive and negative 
patients with BMI > 30 
BMI >30 
 RDI < 15 (14 patients) RDI > 15 (66 patients)  
 X SD X SD p 
RDI 6.81 5.01 48.26 19.17 0.000 
Age (years) 48.21 10.76 48.74 8.62 NS 
BMI (kg/m^2) 32.14 1.59 34.38 3.11 0.011 
TG (mmol/l) 1.85 0.49 1.90 0.28 NS 
TC (mmol/l) 5.12 0.53 5.33 0.35 NS 
HDL (mmol/l) 1.37 0.25 1.30 0.23 NS 
LDL (mmol/l) 2.94 0.60 3.08 0.55 NS 
RDI = Respiratory disturbance index; BMI = Body mass index; TG = Triglycerides; TC = 
Total cholesterol; HDL= High-density lipoprotein cholesterol; LDL = Low-density lipoprotein 
cholesterol. 
 
When all parameters were analysed with 
multiple linear regressions, only BMI, total cholesterol 
levels and LDL levels were found to be independent 
predictors of OSA (Table 4). 
Table 4: Independent predictors of OSA 
 OR 95%CI p 
BMI 1.6 1.39-1.83 0.000 
TC 1.73 1.38-2.16 0.000 
LDL 1.47 1.19-1.81 0.000 
BMI = Body mass index; TC = Total cholesterol; LDL = Low-density lipoprotein cholesterol. 
 
Discussion  
 
OSA is the potent risk factor for metabolic 
disorders. The mechanisms through which OSA may 
worsen metabolism are complex. It may trigger 
several pathological mediating pathways (sympathetic 
activation, neurohumoral changes, glucose 
homoeostasis disruption, inflammation and oxidative 
stress) through chronic intermittent hypoxia (CIH), and 
these may ultimately cause deterioration in the 
metabolic function [14, 15]. According to previous 
studies, the prevalence of OSA is increased fourfold in 
patients with obesity. Obesity plays a major part in the 
development of the metabolic syndrome, which 
consists of insulin resistance, diabetes or impaired 
glucose tolerance, hypertension, and lipoproteinemia 
[16]. In this study, we have demonstrated that OSA 
positive patients had significantly higher level of 
triglycerides, total cholesterol and decreased HDL 
cholesterol levels versus OSA negative patients. LDL 
was also higher in OSA patients but with no significant 
value.  
There were statistically significant differences 
in BMI between OSA positive and negative patients. 
So, the question is, does OSA affect lipid metabolism 
by itself or obesity is playing the major role in 
metabolic changes in these groups of patients. The 
relationships between OSA and various lipid 
parameters have not been extensively investigated 
like other components in the metabolic syndrome and 
the results have been more diverse. Studies of sleep 
clinic cohorts have consistently reported a higher 
prevalence of dyslipidemia in OSA positive subjects 
compared to those without OSA [17, 18].  
The American Heart Health Sleep Study 
reported that apnea-hypopnea index (AHI) was 
inversely related to HDL-cholesterol levels in younger 
men and women, but not in older men, and 
triglyceride levels in younger men and women only 
[19]. In contrast, Lam et al. evaluated 255 patients 
between 30 and 60 years, and they did not find the 
association between OSA and HDL or TG levels, after 
controlling for confounding variables [20]. In our study, 
after dividing patients according to BMI, OSA positive 
patients with BMI < 30 had statistically significant 
higher levels of triglycerides and total cholesterol, and 
statistically significantly lower levels of HDL versus 
OSA negative patients with BMI ≤ 30. This result is 
corresponding with previously cited studies [6-8, 9, 
17-19]. However, several studies that were searching 
for an association between metabolic syndrome and 
normal weight, over weight and obese patients, 
reported that prevalence of metabolic syndrome in 
non-obese patients (BMI 25.0-26.9 kg/m^2) is 
between 9.6-22.5%, depending on ethnicity and sex 
[21, 22]. So the possibility that OSA mechanisms are 
worsening lipid metabolism in a non obese group of 
patients is very high rather that weight gain. In obese 
patients, both OSA positive and OSA negative, there 
were no statistically significant differences in lipid 
blood levels. This result is corresponding with others 
studies. Sahin et al. in their study found out that OSA 
positive obese patients had statistically significant 
higher levels of lipids compared to OSA positive 
patients with normal weight. But in obese patients, 
both OSA positive and OSA negative, there were no 
statistically significant differences in blood levels of 
lipids [23]. Sharma et al. compared three groups of 
patients, 40 obese OSA positive patients, 40 obese 
OSA negative patients and 40 normal weight OSA 
negative patients and found that there was no 
difference in metabolic status between obese OSA 
positive and obese OSA negative patients [24]. 
Schäfer et al. found no relationship between OSA and 
concentration of lipoproteins in 81 male subjects [25]. 
Results from national surveys suggest that 
dyslipidemias are the most common comorbidities 
associated with a range of body mass indices (BMI), 
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with substantial increases found with increased body 
weight. It is estimated that about 68% of obese adults 
in the National Health and Nutrition Examination 
Survey population had metabolic abnormalities [26]. 
However, the limiting factor of this study may be not 
so large number of patients, particularly the small 
number of OSA negative patients with a BMI > 30. It 
should be noted that patients with previous history 
and treatment of diabetes and lipid disorders were 
excluded from the study. 
 In conclusion, OSA and obesity are the potent 
risk factor for dyslipidemias. OSA could play the 
significant part in worsening of lipid metabolism in 
non-obese patients. But in obese patients, the extra 
weight makes the metabolic changes of lipid 
metabolism, and the roll of OSA is not that very 
important like in non-obese patients.
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